Sponsoring the Targeted Cancer Therapy World Congress 2010 is a time and cost-effective opportunity to develop existing and new business.
Sponsorship packages offer your company thought-leadership positioning, branding, and the opportunity to set up face-to-face meetings with hundreds of decision makers from your target market in just 3 working days.
Karsten Witt, MD is Sr. Vice President, Pharmaceutical Operations at OSI Pharmaceuticals, a mid-sized company committed to developing personalized medicine for oncology patients. At OSI, he has been intimately involved in the clinical development of the small-molecule, EGFR tyrosine kinase inhibitor Tarceva® (erlotinib) for NSCLC and pancreatic cancer. This has included assessing predictive biomarkers to identify patients who may derive most benefit.
Appearing:
DAY 3 THURSDAY 23 SEPTEMBER – CLINICAL TRIALS, COLLABORATIONS & COMBINATION THERAPY
10.40am
SATURN trial case study
Dr. Karsten Witt,
Senior Vice President Pharmacuetical Operations, OSI Pharmaceuticals, a subsidary of Astellas
Sponsoring Targeted Cancer
Therapy World Congress 2010
is a time and cost-effective opportunity to develop
existing and new business.
Sponsorship packages offer your company thought-leadership positioning, branding, and the opportunity to set up face-to-face meetings with hundreds of decision makers from your target market in just 3 working days.
